BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26826383)

  • 1. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling.
    Yan H; Guo BY; Zhang S
    Biochem Biophys Res Commun; 2016 Feb; 470(4):947-54. PubMed ID: 26826383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.
    Han Z; Feng J; Hong Z; Chen L; Li W; Liao S; Wang X; Ji T; Wang S; Ma D; Chen G; Gao Q
    Biochem Biophys Res Commun; 2013 May; 435(2):188-94. PubMed ID: 23665025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
    Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
    Zhou B; Sun C; Li N; Shan W; Lu H; Guo L; Guo E; Xia M; Weng D; Meng L; Hu J; Ma D; Chen G
    Int J Oncol; 2016 May; 48(5):2087-97. PubMed ID: 26983899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.
    Tao L; Huang G; Wang R; Pan Y; He Z; Chu X; Song H; Chen L
    Sci Rep; 2016 Dec; 6():38408. PubMed ID: 27922075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
    Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
    Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
    Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
    Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
    Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
    Sheng WJ; Jiang H; Wu DL; Zheng JH
    Braz J Med Biol Res; 2013 Aug; 46(8):650-8. PubMed ID: 23969971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
    Park J; Park SY; Kim JH
    Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cytoplasmic translocation of Cx32 mediates cisplatin resistance in ovarian cancer cells.
    Wu W; Fan L; Bao Z; Zhang Y; Peng Y; Shao M; Xiang Y; Zhang X; Wang Q; Tao L
    Biochem Biophys Res Commun; 2017 May; 487(2):292-299. PubMed ID: 28412364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
    Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
    Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.